Latest News
Jubilant Therapeutics reports preliminary clinical data from Phase 1/2 study in myeloproliferative neoplasms at SOHO 2026
16 September 2026 - Jubilant Therapeutics Inc, a US-based clinical-stage biopharmaceutical company advancing precision therapies for hematological malignancies, announced on Tuesday the presentation of the first clinical data from its ongoing Phase 1...
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
16 September 2026 - Skyhawk Therapeutics Inc, a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announced on Tuesday the final 15-month results from its Phase 1/2 clinical trial evaluat...
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
16 September 2026 - Colombian biotechnology company VaxThera S.A.S. and US-based Codagenix Inc, a clinical-stage biotechnology company focused on synthetic biology-based vaccines, announced on Tuesday an agreement on terms for VaxThera to exclusively...
MaaT Pharma receives negative CHMP trend vote for MaaT013
15 September 2026 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) disclosed on Tuesday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative trend opinion ...
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
15 September 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that it has agreed to acquire a potential best-in-class trispecific T cell-engager (TCE) from privately held biotechnology company Chimagen Biosciences.Th...